Invion (AU:IVX)
ASX:IVX
Want to see AU:IVX full AI Analyst Report?
IVX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.20
Previous CloseN/A
Volume36.17K
Average Volume (3M)97.01K
Market Cap
AU$5.82M
Enterprise ValueAU$6.50M
Total Cash (Recent Filing)AU$137.54K
Total Debt (Recent Filing)AU$627.68K
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding96,965,320
10 Day Avg. Volume121,261
30 Day Avg. Volume97,006
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PDT Tech & Research PartnershipsInvion's proprietary focus on photodynamic therapy combined with active collaborations with research institutions builds durable technical expertise and trial capabilities. These partnerships can de-risk development, accelerate clinical validation and support future licensing or co-development over months to years.
Low Leverage (no Debt)A zero-debt capital structure reduces fixed financing costs and lowers default risk, giving management flexibility to time fundraising or seek non-dilutive partner funding. Over a multi-month horizon this conservatism supports survival while development programs progress.
Development Funding & Licensing Revenue ModelReliance on development funding, milestone payments and licensing provides alternative revenue streams to product sales, enabling ongoing R&D without immediate commercial revenue. Structurally this model can extend runway and attract strategic partners who share development costs and risks.
Bears Say
Zero Revenue And Widening LossesA collapse to zero reported revenue alongside a materially larger net loss signals the company is not converting development into commercial receipts. Persisting operating deficits impair long-term viability, erode investor confidence and make funding future trials or commercialization more difficult.
Persistent Negative Operating Cash FlowChronic cash burn forces reliance on external funding or partner arrangements. Over several months this constrains strategic options, risks dilutive capital raises or reduced R&D scope, and may delay pivotal trials or commercialization steps absent sizable partner commitments.
Shrinking Equity And Asset BaseDeclining shareholders' equity and assets indicate accumulated losses are eroding the balance sheet. This reduces financial flexibility to absorb setbacks, increases fundraising urgency, and can weaken bargaining positions in licensing or partnership negotiations over the medium term.
Invion News
IVX FAQ
What was Invion’s price range in the past 12 months?
Invion lowest share price was AU$0.06 and its highest was AU$0.20 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is AU$5.82M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 124 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -AU$0.042 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.042.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 96,965,320 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -AU$0.042 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in AU:IVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IVX Sentiment 70%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
-150.48%
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion (IVX) is a biotechnology company focused on the research, development, and commercialization of Photodynamic Therapy (PDT) for the treatment of various cancers. Operating primarily in the healthcare and pharmaceutical sectors, Invion is dedicated to advancing its novel technologies to offer innovative treatment solutions that can improve patient outcomes. The company's core products include its proprietary PDT compounds and related systems that leverage light-activated processes to target and destroy cancer cells.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Options Prices
Currently, No data available
---